Target intelligence / Profile preview

Apical membrane antigen 1 (Plasmodium vivax) (PvAMA1)

Target
PvAMA1
Molecular classification
Adhesin, Type I integral membrane protein, Microneme protein
01

Overview

Apical membrane antigen 1 (AMA1) is a highly conserved, type I integral membrane protein located in the micronemes of Plasmodium vivax and other apicomplexan parasites (Pizarro et al., 2005, PubMed: 15806113). It is essential for the invasion of host cells, facilitating the entry of merozoites into erythrocytes and sporozoites into hepatocytes (Remarque et al., 2008, PubMed: 18234169). During the invasion process, AMA1 is translocated to the parasite surface where it binds to rhoptry neck protein 2 (RON2), forming a moving junction that is critical for internalization (Srinivasan et al., 2011, PubMed: 21478870). Due to its indispensable role in the parasite life cycle, PvAMA1 is a major target for blood-stage malaria vaccines and inhibitory molecules (Arevalo-Herrera et al., 2015, PubMed: 25644337). However, the high degree of genetic polymorphism in the PvAMA1 gene leads to significant antigenic variation, which presents a major challenge for developing a vaccine that provides broad protection against diverse parasite strains (Arnott et al., 2014, PubMed: 24454710). Current therapeutic strategies focus on inducing neutralizing antibodies or using peptides to disrupt the AMA1-RON2 interaction (Vulliez-Le Normand et al., 2012, PubMed: 22566538).

Other names
AMA-1PvAMA-1Apical membrane antigen 1
02

Mechanism of action

Inhibition of the interaction between AMA1 and RON2 to prevent the formation of the moving junction and subsequent parasite entry into host cells (Srinivasan et al., 2011, PubMed: 21478870).

03

Biological functions

Host cell invasionCell adhesionMerozoite invasionSporozoite invasionTight junction formation
04

Disease associations

MalariaInfection
05

Safety considerations

High genetic polymorphismStrain-specific immunityImmune evasion
06

Interacting drugs

PvAMA1-based vaccines

3 more in the full profile.

07

Biomarkers

Anti-PvAMA1 antibody titersPvAMA1 genetic polymorphisms

Beyond the preview

Go deeper on Apical membrane antigen 1 (Plasmodium vivax) (PvAMA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apical membrane antigen 1 (Plasmodium vivax) (PvAMA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call